Enzanamo contains Enzalutamide, an oral nonsteroidal anti-androgen medication used primarily for the treatment of prostate cancer, especially metastatic castration-resistant prostate cancer (mCRPC). It works by blocking androgen receptors, thereby inhibiting the growth and proliferation of prostate cancer cells that depend on androgens like testosterone.

Mechanism of Action

• Enzalutamide binds to androgen receptors on prostate cancer cells, preventing activation by testosterone or dihydrotestosterone.

• It inhibits androgen receptor translocation to the nucleus, DNA binding, and coactivator recruitment.

• By blocking androgen receptor signaling, it reduces tumor growth and progression in androgen-dependent prostate cancer.

  Uses

  • Treatment of metastatic castration-resistant prostate cancer (mCRPC).

  • Used in non-metastatic castration-resistant prostate cancer to delay disease progression.

  • Can be combined with androgen deprivation therapy (ADT) for advanced prostate cancer.

  • Helps reduce tumor growth and prolong survival in patients with prostate cancer.

    Adverse Effects

    • Fatigue, weakness

    • Hot flashes

    • Nausea or diarrhea

    • Joint or muscle pain